United Therapeutics

Investor's Business Daily

United Therapeutics (UTHR) was cut to sell from neutral by Goldman Sachs, citing a setback for a key pipeline drug, oral Remodulin, and the ongoing Sandoz patent challenge of versions of Remodulin. Goldman kept a $50 price target. United Therapeutics fell 3.6% to 50.26.

View Comments (0)